Spyre Therapeutics

This week marks two significant milestones for Spyre as we celebrate our one-year anniversary and announce the initiation of our first clinical trial evaluating SPY001, an investigational half-life extended anti-α4β7 monoclonal antibody, in healthy volunteers. We are proud of the hard work and dedication that were required to reach this stage and excited about our future with two additional programs expected to enter clinical studies in the next year. Together, we hope these investigational therapies will lead to a meaningful step forward in the treatment of IBD. Learn more: https://lnkd.in/gi-ebw4A #IBD

This week, Spyre will attend the 2024 Jefferies Global Healthcare Conference, where our CEO Cameron Turtle will participate in a fireside chat and our team will host investor meetings regarding our investigational next-generation treatment options for patients with inflammatory bowel disease. To learn more about our approach and watch the live webcast, head to ir.spyre.com. #JefferiesHealthcare #IBD

We are excited to introduce our first #InSpyred employee spotlight, where we recognize employees who inspire us every day. Olivia Ballew, PhD, joined Spyre in November as a Senior Scientist on our non-clinical R&D team. Growing up, Olivia was always interested in science, but it was her genetics class in college that allowed her to dive into the research that really piqued her interest and solidified her passion for the work that she does. When she isn’t working, Olivia is a competitive marathon runner and spends her free time training for upcoming races.

May 19 is #WorldIBDDay, and we’re raising awareness for the millions of people living with inflammatory bowel disease (IBD). Not only does IBD have severe physical impacts, but the disease can also be extremely isolating when those around you don’t understand the severity of your symptoms or how to provide support. Spyre is committed to researching and developing treatment options to improve the experience for all IBD patients. Hear from our experts Joshua R Friedman and Deanna Nguyen to learn more about IBD and what is needed in the treatment landscape. #IBDAwareness #IBD

Today, we welcome Sandra Milligan, M.D., J.D., to Spyre’s Board of Directors! Dr. Milligan has led a remarkable career with her deep understanding of clinical development and regulatory paths, including in IBD. We are confident Dr. Milligan’s expertise and commitment to patients will help us drive forward our portfolio. Please join us in welcoming Dr. Milligan to the Board! Read the full news here: https://bit.ly/4dJjP8M #IBD #BioTech

This week, Spyre is attending the Bank of America Securities 2024 Healthcare Conference in Las Vegas, NV. We are excited to host investor meetings at the conference and discuss our broad pipeline of potentially best-in-class antibodies. #antibody #TL1A #α4β7 #IBD

Today, we announced our first quarter financial results for 2024. We are thrilled to be on the cusp of entering clinical studies with our lead programs to research their potential as novel treatment options for those living with IBD. See our latest news release for additional details: https://bit.ly/3UCHVtn Stay tuned as we look forward to an exciting year ahead! #antibody #TL1A #α4β7 #IBD

We're #hiring a new Senior Scientist, Translational Science in United States. Apply today or share this post with your network.

We're #hiring a new Clinical Trial Manager, Development Operations in United States. Apply today or share this post with your network.

We're #hiring a new Senior Director, CMC Operations in United States. Apply today or share this post with your network.